Interview with the President and CEO: Mirati Therapeutics, Inc. (MRTX)
Charles M. Baum was appointed President and Chief Executive Officer and board member of Mirati Therapeutics, Inc., in November 2012. Prior to joining the company, he was Senior Vice President for Biotherapeutic Clinical Research within Pfizer’s Worldwide Research & Development division. Dr. Baum was at Pfizer since 2003, serving in roles of increasing responsibility including as Vice President and Head of Oncology Development and as Chief Medical Officer for Pfizer’s Biotherapeutics and Bioinnovation Center. He was responsible for the development of the oncology portfolio, including Axitinib/Inlyta; Crizotinib/Xalkori; and the approval of sunitinib/Sutent, for the treatment of gastrointestinal stromal tumor and renal cell carcinoma. Prior to joining Pfizer, Dr. Baum was responsible for the Phase I-IV development of several oncology compounds at Schering-Plough, including temozolomide/Temodar, which was approved for the treatment of patients with advanced brain tumors. His career has included academic and hospital positions at Stanford and Emory universities, as well as positions of increasing responsibility within the pharmaceutical industry. Dr. Baum received his M.D. and Ph.D. in immunology from Washington University School of Medicine in St. Louis, Missouri, and completed his postdoctoral work and residency at Stanford University, California. Dr. Baum has received research support from the National Institutes of Health and the American Cancer Society, published more than 50 peer-reviewed manuscripts, and holds a number of patents and patent applications. Profile
TWST: Please begin with a brief summary of Mirati Therapeutics and its current initiatives.
Dr. Baum: Mirati is a biotechnology company focused on oncology drug development. We’re